TACE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tace, and when can generic versions of Tace launch?
Tace is a drug marketed by Sanofi Aventis Us and is included in three NDAs.
The generic ingredient in TACE is chlorotrianisene. There are four drug master file entries for this compound. Additional details are available on the chlorotrianisene profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TACE?
- What are the global sales for TACE?
- What is Average Wholesale Price for TACE?
Summary for TACE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 69 |
Patent Applications: | 3,472 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TACE at DailyMed |
![TACE drug patent expirations Drug patent expirations by year for TACE](/p/graph/s/t/TACE-patent-expirations.png)
US Patents and Regulatory Information for TACE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | TACE | chlorotrianisene | CAPSULE;ORAL | 008102-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sanofi Aventis Us | TACE | chlorotrianisene | CAPSULE;ORAL | 011444-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sanofi Aventis Us | TACE | chlorotrianisene | CAPSULE;ORAL | 016235-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |